BioSpace News Archive

Ardelyx, Inc. (Nasdaq: ARDX) today announced the resubmission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the approval of XPHOZAH (tenapanor) for the control of serum phosphate in adult patients with chronic kidney disease on dialysis who have had an inadequate response or intolerance to a phosphate binder therapy.

Vor Bio, a clinical-stage cell and genome engineering company, announced that it will participate in the following upcoming investor conferences.

ProSomnus, Inc. today announced the publication of four abstracts in the Journal of Dental Sleep Medicine.

Cocrystal Pharma, Inc. (Nasdaq: COCP) (Cocrystal or the Company) announces the acceptance of an oral presentation containing new data from the Company’s CC-42344 Phase 1 influenza A study at the 7th Annual International Society for Influenza and Other Respiratory Virus Diseases’ (ISIRV) Antiviral Group Conference.

Human Immunology Biosciences (HI-Bio™), today announced the appointment of Uptal Patel , M.D., as Chief Medical Officer.

Chiesi Global Rare Diseases announced a U.S. Networkwide Sponsorship of BioInnovation Labs, the leading developer and operator of life science coworking spaces with 12 active facilities and a growing network in the U.S. and internationally.

Lisata Therapeutics, Inc. and WARPNINE Incorporated today announced the treatment of the first patient in the iLSTA Trial of Lisata’s LSTA1 in combination with standard-of-care chemotherapy and immunotherapy as a first-line treatment in locally advanced non-resectable pancreatic ductal adenocarcinoma (“PDAC”).

Xenocor, creator of the FDA cleared Saberscope, the world’s first true HD, fog-free, articulating, single-use laparoscope, announced a $10 million Series A funding led by GenHenn Venture fund.

Rehabilitation robotics company Harmonic Bionics announced today that the company has registered their flagship exoskeleton Harmony SHR™ with the FDA as a Class II 510(k)-exempt device.

Autobahn Therapeutics today announced that it has initiated the multiple ascending dose (MAD) portion of its Phase 1 study of ABX-002 in healthy subjects.